01—Abstract
Summary
Summary of the 10-K filed February 29, 2016. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies, built on its rHuPH20 enzyme platform (ENHANZE Technology) and its lead candidate PEGPH20, which is in Phase 2 and Phase 3 testing for stage IV pancreatic ductal adenocarcinoma.
Revenue rose to $135.1 milliona in 2015 from $75.3 million in 2014, driven by $58.0 million in revenues under collaborative agreements (including $25.0 million from Lilly and $23.0 million from AbbVie license fees) and $31.0 million in royalties. Net loss narrowed to $32.2 million, or $0.25 per share, from $68.4 million, while the company has never been profitable and had an accumulated deficit of $482.7 million at year-end. Research and development expense rose to $93.2 million, with PEGPH20 program expense increasing to $75.6 million from $34.9 million, reflecting expanded clinical activity.
Cash, cash equivalents and marketable securities were $108.3 millionb at December 31, 2015, which the company says will fund operations for at least the next twelve months. Subsequent to year-end, in January 2016, Halozyme Royalty received a $150 million royalty-backed loan secured by royalties from the Roche and Baxalta collaborations, and the company expects cash to increase by approximately $35 million to $55 million in 2016.
Key risks include the April 2014 clinical hold on Study 109-202 related to thromboembolic (TE) event rates, which the company says could be halted again if FDA finds safety imbalances; the company's reliance on contract manufacturers and a single collaborator concentration (Roche represented 42%c of 2015 revenues); and the need to raise additional capital in the future. The Phase 3 Study 109-301 began in the first quarter of 2016, with a companion diagnostic being developed with Ventana.
02—Key points
Key Highlights
- Total revenues increased to $135.1 million in 2015 from $75.3 million in 2014; net loss narrowed to $32.2 million ($0.25 per share) from $68.4 million.
- Revenues under collaborative agreements were $58.0 million in 2015, including $25.0 million from Lilly and $23.0 million from AbbVie license fees; royalty revenue was $31.0 million versus $9.4 million in 2014.
- R&D expense rose to $93.2 million, with PEGPH20 program expense of $75.6 million, up from $34.9 million in 2014.
- Cash, cash equivalents and marketable securities totaled $108.3 million at December 31, 2015; the company believes this is sufficient for at least the next twelve months.
- A $150 million royalty-backed loan was received in January 2016 through subsidiary Halozyme Royalty, secured by royalties from the Roche and Baxalta collaborations.
- Roche accounted for 42% of total 2015 revenues, with Lilly at 19% and AbbVie at 17%, indicating customer concentration.
- The company had an accumulated deficit of $482.7 million and has never been profitable; it expects significant operating losses over the next few years.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2015, Halozyme Therapeutics lost $0.24.
- Revenue$135.1M100.0%
- Cost of revenue−$29.2M21.7%
- Gross profit$105.8M78.3%
- Operating costs−$133.3M98.7%
- Operating income−$27.5M20.3%
- Interest, other & tax−$4.8M3.5%
- Net income−$32.2M23.9%
04—Financials
Financial Highlights
Figures from 10-KFY2015filed February 29, 2016Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $135.06M$75.33M | +79.3% |
| Cost of Revenue | $29.25M$22.73M | +28.7% |
| Gross Profit | $105.81M$52.60M | +101.2% |
| R&D Expenses | $93.24M$79.70M | +17.0% |
| SG&A Expenses | $40.03M$35.94M | +11.4% |
| Operating Expenses | $162.51M$138.37M | +17.4% |
| Operating Income | -$27.45M-$63.04M | +56.5% |
| Interest Expense | $5.20M$5.60M | −7.1% |
| Net Income | -$32.23M-$68.38M | +52.9% |
| EPS (Basic) | $-0.25$-0.56 | +55.4% |
| EPS (Diluted) | $-0.25— | — |
| Shares Outstanding (Basic) | 126.70M122.69M | +3.3% |
| Shares Outstanding (Diluted) | 126.70M— | — |
05—Questions
Frequently Asked Questions
What is the status of the PEGPH20 pancreatic cancer program?
PEGPH20 is in Phase 2 (Study 109-202) and Phase 3 (Study 109-301) testing for stage IV pancreatic ductal adenocarcinoma. Study 109-202 was placed on clinical hold in April 2014 over a possible difference in thromboembolic event rates and reinitiated in July 2014 under a revised protocol. The Phase 3 study began in the first quarter of 2016, with first dosing expected in March 2016, and mature PFS data from Study 202 Stage 2 are projected for the fourth quarter of 2016.
How much cash does Halozyme have and how is it being funded?
Cash, cash equivalents and marketable securities were $108.3 million at December 31, 2015. The company received a $150 million royalty-backed loan in January 2016 and expects cash and cash equivalents to increase by approximately $35 million to $55 million for 2016, including $25 million from Lilly and the $150 million loan. The company says it may need to raise additional capital in the future.
What are the main risks to investors identified in the filing?
Key risks include the possibility that the Study 202 trial may be halted again if the FDA determines that safety imbalances, including TE events, occur; dependence on contract manufacturers Avid and Cook for bulk rHuPH20; reliance on collaborators such as Roche, which generated 42% of 2015 revenues; the need for additional capital that may dilute shareholders; and restrictive covenants in the Loan Agreement and royalty-backed Credit Agreement.
What drove the increase in revenue and the narrower net loss in 2015?
Revenue growth was driven by $48.0 million in license fees from the AbbVie and Lilly collaborations, royalty revenue that rose to $31.0 million from $9.4 million (mainly from increased Herceptin SC sales by Roche), and product sales that increased to $46.1 million from $37.8 million. Operating expenses rose to $162.5 million from $138.4 million, but the revenue gain outpaced that increase, reducing the net loss to $32.2 million from $68.4 million.
What is Hylenex recombinant and how does it contribute to the business?
Hylenex recombinant is the company's only marketed proprietary product, a formulation of rHuPH20 approved by the FDA for subcutaneous fluid administration, increasing dispersion and absorption of other injected drugs, and subcutaneous urography. Product sales of Hylenex recombinant were $16.1 million in 2015 compared with $13.2 million in 2014. The company sells it in the U.S. through wholesale distributors, with ICS as its exclusive distributor.
06—Continue